The role of interleukin 1 in the development of human diseases: focus on Anakinra (IL-1 receptor antagonist)

The role of interleukin 1 in the development of human diseases: focus on Anakinra (IL-1 receptor antagonist)

According to modern concepts, human immune-mediated inflammatory diseases (IMIDs), depending on the prevailing mechanisms of immunopathogenesis, are divided into two main categories – autoimmune and autoinflammatory.At the same time, both autoimmune and autoinflammatory mechanisms are involved in th...

Full description

Bibliographic Details
Main Authors:	E. L. Nasonov, M. Yu. Samsonov
Format:	Article
Language:	Russian
Published:	IMA PRESS LLC 2022-07-01
Series:	Научно-практическая ревматология
Subjects:	systemic autoinflammatory diseases interleukin 1 anakinra covid-19
Online Access:	https://rsp.mediar-press.net/rsp/article/view/3172

Similar Items

Schnitzler syndrome refractory to anakinra: successful treatment with canakinumab
by: Angel Luis Salcedo-Mingoarranz, et al.
Published: (2023-12-01)

A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study
by: Antonio Vitale, et al.
Published: (2016-10-01)

Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report
by: Marco Franzetti, et al.
Published: (2020-08-01)

Peri- and Postoperative Treatment with the Interleukin-1 Receptor Antagonist Anakinra Is Safe in Patients Undergoing Renal Transplantation: Case Series and Review of the Literature
by: Catharina M. Mulders-Manders, et al.
Published: (2017-05-01)

Problems of immunopathology and prospects for pharmacotherapy of idiopathic recurrent pericarditis: Using an interleukin 1 inhibitor (Anakinra)
by: E. L. Nasonov, et al.
Published: (2023-03-01)

Delayed Use of the Recombinant Human IL-1 Receptor Antagonist Anakinra in Five COVID-19 Patients with Pulmonary Fibrosis and Persistent Hypoxaemia: A Preliminary Report
by: Daniel Nan, et al.
Published: (2021-10-01)

Efficacy and safety of anakinra and canakinumab in PSTPIP1-associated inflammatory diseases: a comprehensive scoping review
by: Juan Luis Sanz-Cabanillas, et al.
Published: (2024-01-01)

Real-Life Indications of Interleukin-1 Blocking Agents in Hereditary Recurrent Fevers: Data From the JIRcohort and a Literature Review
by: Caroline Vinit, et al.
Published: (2021-11-01)

ROLE OF INTERLEUKIN 1 IN THE DEVELOPMENT OF HUMAN DISEASES
by: E. L. Nasonov, et al.
Published: (2016-03-01)

The use of Anakinra in a patient with a combination of two autoinflammatory diseases: Familial Mediterranean fever and gout
by: M. S. Eliseev, et al.
Published: (2023-04-01)

ACO/ARO/AIO-21 - Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group
by: Maximilian Fleischmann, et al.
Published: (2022-05-01)

Pilot Study of IL-1 Antagonist Anakinra for Treatment of Endometriosis
by: Sullender RT, et al.
Published: (2024-09-01)

The effect of anakinra on retinal function in isolated perfused vertebrate retina
by: Mahdy Ranjbar, et al.
Published: (2017-03-01)

Experiences with IL-1 blockade in systemic juvenile idiopathic arthritis – data from the German AID-registry
by: Elke Lainka, et al.
Published: (2021-03-01)

The interleukin 1 receptor antagonist anakinra to reduce disease severity of palmoplantar pustulosis in adults: APRICOT RCT and PLUM mechanistic study
by: Suzie Cro, et al.
Published: (2022-03-01)

Comparison of Tocilizumab and Anakinra in the Treatment of COVID-19: A Single-Center Experience
by: Bengisu Pınar Acat, et al.
Published: (2022-08-01)

Use of Anakinra in steroid dependent recurrent pericarditis: a case report and review of literature
by: Vinay Kumar Thallapally, et al.
Published: (2021-07-01)

Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes
by: Antonio Vitale, et al.
Published: (2020-02-01)

Differential Response to Interleukin‐1 Blockade With Anakinra on Cardiorespiratory Fitness in Patients With Heart Failure With Preserved Ejection Fraction Stratified According to Left Ventricular Ejection Fraction
by: Michele Golino, et al.
Published: (2023-09-01)

Woronoff Ring in Deficiency of Interleukin-36 Receptor Antagonist (DITRA)
by: Daniel Morgado-Carasco, et al.
Published: (2019-12-01)

Effects of interleukin-1 receptor antagonism in women with polycystic ovary syndrome—the FertIL trial
by: Milica Wälchli-Popovic, et al.
Published: (2024-09-01)

Subcutaneous anakinra in the management of refractory MIS-C in France
by: Perrine Dusser, et al.
Published: (2024-02-01)

Efficacy of Anakinra on Multiple Coronary Arteries Aneurysms in an Infant with Recurrent Kawasaki Disease, Complicated by Macrophage Activation Syndrome
by: Grazia Bossi, et al.
Published: (2022-05-01)

The Comparative Effects of Anakinra and Tocilizumab on Inflammation and Cerebral Vasospasm in an Experimental Subarachnoid Hemorrhage Model
by: Güven Kılıç, et al.
Published: (2024-12-01)

Fighting autoinflammation in FIRES: The role of interleukins and early immunomodulation
by: Marco Perulli, et al.
Published: (2022-01-01)

Tocilizumab versus anakinra in COVID-19: results from propensity score matching
by: Robin Arcani, et al.
Published: (2023-05-01)

Erratum in: Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease
by: Roberto Ravasio, et al.
Published: (2020-09-01)

Interleukin-1 is a Biological Marker in Heart Failure
by: A. M. Alieva, et al.
Published: (2022-12-01)

A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID‐19
by: Amir Behnam Kharazmi, et al.
Published: (2022-02-01)

Case report: Novel compound heterozygous IL1RN mutations as the likely cause of a lethal form of deficiency of interleukin-1 receptor antagonist
by: Elena Urbaneja, et al.
Published: (2024-04-01)

Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma
by: Madelyn Espinosa-Cotton, et al.
Published: (2019-03-01)

An open label trial of anakinra to prevent respiratory failure in COVID-19
by: Evdoxia Kyriazopoulou, et al.
Published: (2021-03-01)

Deficiency of interleukin-1 receptor antagonist: An updated review of the pathogenesis, clinical characteristics, and treatments
by: Spencer Fang, et al.
Published: (2024-12-01)

Use of anakinra in severe COVID-19: A case report
by: Giovanni Filocamo, et al.
Published: (2020-07-01)

Open-label use of Anakinra (Kineret) in the treatment of patients with osteoarthritis
by: Craig Davis Scoville, et al.
Published: (2017-01-01)

Investigation of the Effect of Anakinra on Pentylenetetrazole-Induced Epileptic Seizures in Mice
by: Ahmet Kemal FİLİZ, et al.
Published: (2021-08-01)

Failure of anti Interleukin-1 β monoclonal antibody in the treatment of recurrent pericarditis in two children
by: Sara Signa, et al.
Published: (2020-06-01)

Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation
by: Emanuel Della-Torre, et al.
Published: (2021-04-01)

Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab
by: Annette Langer-Gould, et al.
Published: (2020-10-01)

The use of Anakinra in treatment of calcium pyrophosphate crystal deposition disease: Analysis of own experience and a literature review
by: M. S. Eliseev, et al.
Published: (2022-12-01)